Recent Developments across Genetic Technologies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE depicts trends across genetic technologies. The corresponding clinical trial analysis for next-generation cancer immunotherapies is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & We

Table of Contents

Recent Developments across Genetic TechnologiesGenetic Technology AdvancesNewcastle Fertility Centre Granted Licence for Mitochondrial Replacement TherapyEnhancing Cancer Immunotherapies through Probody™ Therapeutics AveXis’ Novel Gene Therapy Candidate, AVXS-101, Completes Phase I TrialeGenesis Raises $38 Million to Use CRISPR Technology for XenotransplantationClinical Trial Analysis and Industry InteractionsClinical Trial Analysis for Next-generation Cancer ImmunotherapiesSummary of Key Contacts

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.